Jupiter, FL - March 23, 2015 – GLG Pharma, LLC, focused on developing drugs to prevent/treat cancer as well as other diseases mediated by dysfunctional STAT3 signaling, announced a NCI data presentation at the 2015 American Association of Cancer Research (AACR) Annual Meeting being held April 18-22, 2015 at the Pennsylvania Convention Center in Philadelphia, PA. The study was sponsored by the PREVENT Cancer program of the National Cancer Institute of the NIH. The PREVENT Program is a National Cancer Institute-supported pipeline to bring new and novel cancer preventing interventions and biomarkers through preclinical development towards clinical trials.
The details for the data presentation at AACR are as follows:
Poster Presentation
|
Abstract Number: |
4657 |
|
Presentation Title: |
Targeting STAT3 for mammary cancer prevention in MMTV/Neu mice employing the antagonist GLG-302 |
|
Presentation Time: |
Tuesday, Apr 21, 2015, 1:00 PM - 5:00 PM |
|
Location: |
Section 37 |
|
Poster Board Number: |
19 |
|
Author Block: |
Robert H. Shoemaker1, Michael W. Lovell2, John J. Whalen2, Fariba Moeinpour3, Clinton J. Grubbs3. 1National Cancer Institutes, Bethesda, MD; 2GLG Pharma, LLC, Jupiter, FL; 3University of Alabama at Birmingham, Birmingham, AL |
About GLG-302
GLG-302 is an orally available compound designed to target dysfunctional STAT3 signaling in cancer and other diseases. In cancer, dysfunction STAT3 signaling is found in tumors, cancer stem cells and cells that suppress the immune system. Cancer stem cells are an underlying cause of tumor resistance to chemotherapy, recurrence and ultimate disease progression. Immune suppression is associated with ultimate disease progression. In pre-clinical studies, GLG-302 has been shown to suppress the growth of breast cancer and other tumors, in vivo, has been reported to suppress the growth of glioblastoma stem cells and has been reported to modulate the immune microenvironment of glioblastoma, as well as in the blood of cancer patients with urothelial and renal carcinomas, in vitro. GLG-302 was well tolerated in pre-clinical toxicology studies.
About GLG Pharma
Founded in 2009 and located in Jupiter, Florida, GLG Pharma, LLC is a privately held, early stage, biotechnology company developing personalized therapies for patients with cancer and other proliferative diseases. GLG Pharma’s therapeutics are expected to aid in the treatment of a wide variety of cancers and address unmet needs in the multi-billion dollar anti-cancer market with potentially greater efficacy and fewer side effects than existing therapies. For more information on GLG Pharma visit: http://www.glgpharma.com
For information on investing in GLG Pharma visit: http://www.poliwogg.com for Accredited Investors following Regulation D 506(c).
About NCI PREVENT
The PREVENT Cancer Drug Development Program is a National Cancer Institute-supported pipeline to bring new cancer preventing interventions and biomarkers through preclinical development towards clinical trials.
PREVENT is an active NCI partnership with successful applicants to enable the milestone-driven progression of novel cancer preventive chemical or biological agents (singly or in combination) and biomarkers from the lab bench towards proof-of principle clinical testing and registration or validation.
PREVENT is a flexible entry-point system that will optimize and test an agent depending on the stage of development, with the goal of filing an Investigational New Drug Application with the U.S. Food and Drug Administration and entering it into clinical testing. http://prevention.cancer.gov/programs-resources/programs/prevent
|
Contacts: |
|
|
Michael W. Lovell, PhD Executive Vice President GLG Pharma, LLC 601 Heritage Drive, Suite 223 Jupiter, FL 33458 Tel:(904)201-1628 Fax:(904)201-1637 Email: mwlovell@glgpharma.com
|
Hector J. Gomez, MD, PhD President & Chief Executive Officer GLG Pharma, LLC 601 Heritage Drive, Suite 223 Jupiter, FL 33458 Office 561 847-4926 Fax 562 365-6044 Email: hjgomez@glgpharma.com
|
Comments